Regulatory FDA kicks off review of Roche’s Gazyva for wider lupus use PharmaphorumRoche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.RegulatoryImmunology & InflammationRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus. RegulatoryImmunology & InflammationRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapyNext: Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
